Form 8-K - Current report:
SEC Accession No. 0001564590-22-021333
Filing Date
2022-05-26
Accepted
2022-05-26 09:00:18
Documents
13
Period of Report
2022-05-25
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ubx-8k_20220525.htm   iXBRL 8-K 38180
2 EX-99.1 ubx-ex991_6.htm EX-99.1 11841
  Complete submission text file 0001564590-22-021333.txt   184305

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ubx-20220525.xsd EX-101.SCH 5610
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ubx-20220525_lab.xml EX-101.LAB 19317
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ubx-20220525_pre.xml EX-101.PRE 11499
7 EXTRACTED XBRL INSTANCE DOCUMENT ubx-8k_20220525_htm.xml XML 3555
Mailing Address 3280 BAYSHORE BOULEVARD BRISBANE CA 94005
Business Address 3280 BAYSHORE BOULEVARD BRISBANE CA 94005 (415) 328-5504
Unity Biotechnology, Inc. (Filer) CIK: 0001463361 (see all company filings)

EIN.: 264726035 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38470 | Film No.: 22965748
SIC: 2834 Pharmaceutical Preparations